BPI-530616

BPI-530616: sourced facts only. name: "Herein, we report the discovery of a novel potent MALT1 allosteric inhibitor, BPI-530616, which strongly inhibited MALT1 protease activity with subnanomolar IC50, and low off-target activity on other proteases." [DOI:10.1158/1538-7445.am2024-7583]; target: "Herein, we report the discovery of a novel potent MALT1 allosteric inhibitor, BPI-530616, which strongly inhibited MALT1 protease activity with subnanomolar IC50, and low off-target activity on other proteases." [DOI:10.1158/1538-7445.am2024-7583]; developer: "1Betta Pharmaceuticals Co.,Ltd, Hangzhou, China." [DOI:10.1158/1538-7445.am2024-7583]; modality: "Taken together, our research has led to the discovery of a novel, potent, selective, and orally bioavailable small molecule MALT1 inhibitor, BPI-530616." [DOI:10.1158/1538-7445.am2024-7583]; stage: "In vivo, BPI-530616 dose-dependently suppressed tumor growth and inhibited the cleavage of CYLD in OCI-ly3 xenograft mouse model." [DOI:10.1158/1538-7445.am2024-7583]